C3 and lipoprotein glomerulopathy: Alterative pathway dysregulation has been found approximately in 50–70% of patients with C3-glomerulopathy (glomerular C3 deposition) and immune complex-associated membranoproliferative glomerulonephritis (glomerular Ig and complement deposition).